GlassScriptPhysician profile
Suhail A Dar
NPI 1265827810
$908.50
in general payments reported to CMS, 2019-2025
14 companies · $541 in 2025
The $541 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.39 · 2024: $271 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $812.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $324.23 | 2024-2025 | Omnipod |
| Medtronic, INC. | $96.39 | 2021 | |
| Amgen INC. | $92.06 | 2024-2025 | Tepezza, Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $75.61 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $65.58 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Novo Nordisk INC | $58.18 | 2024-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $45.69 | 2024 | |
| Radius Health, INC. | $29.80 | 2025 | Tymlos |
| Boston Scientific Corporation | $25.96 | 2024 | |
| Sequel Med Tech, LLC | $25.62 | 2025 | Twiist |
| Pfizer INC. | $21.63 | 2024 | |
| Abbott Laboratories | $16.77 | 2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.63 | 2025 | Jardiance |
| Astellas Pharma US INC | $15.35 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suhail Dar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.